|
SIK2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.31720231680788E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62519997459754E-10 |
| Normal-vs-Stage2 |
1.78140000528515E-08 |
| Normal-vs-Stage3 |
1.20320420293751E-11 |
| Normal-vs-Stage4 |
5.47779599457954E-11 |
| Stage1-vs-Stage2 |
7.097600E-01 |
| Stage1-vs-Stage3 |
1.778170E-01 |
| Stage1-vs-Stage4 |
2.546600E-01 |
| Stage2-vs-Stage3 |
1.953190E-01 |
| Stage2-vs-Stage4 |
2.152200E-01 |
| Stage3-vs-Stage4 |
9.057600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.12909714700527E-11 |
| Normal-vs-AfricanAmerican |
2.356800E-03 |
| Normal-vs-Asian |
7.26569915343589E-11 |
| Caucasian-vs-AfricanAmerican |
9.897700E-02 |
| Caucasian-vs-Asian |
5.636000E-01 |
| AfricanAmerican-vs-Asian |
6.575700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.58639767988689E-11 |
| Normal-vs-Female |
1.4764001132761E-10 |
| Male-vs-Female |
1.831240E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.9670001445179E-10 |
| Normal-vs-Age(41-60Yrs) |
6.43779474174266E-11 |
| Normal-vs-Age(61-80Yrs) |
3.93619581373628E-11 |
| Normal-vs-Age(81-100Yrs) |
1.462840E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.066800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.172000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.580000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.753800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.391200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.019000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.902330E-03 |
| Classical-VS-Follicular |
4.299800E-01 |
| Classical-VS-Other |
2.586200E-01 |
| Classical-VS-Normal |
1.24400001411118E-09 |
| Tall-VS-Follicular |
4.037700E-02 |
| Tall-VS-Other |
9.406000E-01 |
| Tall-VS-Normal |
2.25530705222354E-12 |
| Follicular-VS-Other |
4.045600E-01 |
| Follicular-VS-Normal |
7.97779953209954E-10 |
| Other-VS-Normal |
8.170600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.58150176182903E-11 |
| Normal-vs-N1 |
4.17930134943845E-11 |
| N0-vs-N1 |
3.006000E-01 |
|
|
